Compare Mesoblast Limited (MESO) vs Royal Bank of Canada (RY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Royal Bank of Canada — how do they compare? Mesoblast Limited trades at $16.36 (market cap $2.17B), while Royal Bank of Canada trades at $210.81 (market cap $289.51B). The key difference: Royal Bank of Canada is far larger — about 133.4× Mesoblast Limited's market cap, and Royal Bank of Canada pays a 2.42% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | RY | |
|---|---|---|
Market Cap | $2.17B | $289.51B |
Sector | Technology | Financials |
52-Week High | $20.96 | $217.87 |
52-Week Low | $12.88 | $128.46 |
Enterprise Value | $2.17B | — |
Dividend Yield | — | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Royal Bank of Canada (RY) trades at $210.37, down 2.35% today, with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows bullish technical signals with moving averages supporting upward momentum, though RSI levels suggest potential overbought conditions. Recent financial performance includes robust revenue growth to $66.53B in 2025 and a healthy net income margin of 31.85%, while the company maintains a solid dividend program with recent increases.
RY presents a mixed outlook with strong fundamentals and analyst support but faces valuation concerns. The company's consistent earnings beats and shareholder returns through dividends and buybacks provide upside potential, though elevated P/E and P/S ratios warrant caution. Key risks include economic sensitivity and competitive pressures in the banking sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →
